Experimental Endocrine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET
| Source:
InveniAI LLC
InveniAI LLC
Guilford, Connecticut, UNITED STATES
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseases
Dr. Alesci’s proven track record in optimizing early-stage drug development of multiple programs in various therapeutic areas will be key as the company leverages its AI-platform to advance and diversify its portfolio
GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) InveniAI
® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announc ....

Salvatore Alesci , Krishnan Nandabalan , School Of Medicine , Scientific Affairs At Takeda Pharmaceuticals , Metabolic Sciences , Us Department Of Health , Human Services , National Institutes Of Health , Allergy At Georgetown University , Research Fellowship In Rheumatology , University Of Messina , Chief Scientific , Gut Brain Axis , Chief Scientist , Strategy Officer , Beyond Celiac , Scientific Affairs , Takeda Pharmaceuticals , Translational Medicine , Experimental Endocrine , Research Fellowship , National Institutes , Special Acts , Service Awards , பள்ளி ஆஃப் மருந்து , அறிவியல் வாழ்க்கைத்தொழில்கள் இல் டாகேடா மருந்துகள் ,